Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720941 · ClinicalTrials.gov registry record · Phase 3
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,110
- Enrollment target
NCT00720941 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,110 participants.
The verdict
NCT00720941, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,110 participants
- Enrollment target
Study Summary
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.
Interventions
- DRUG Sunitinib
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,110 participants |
| Start Date | 2008-08-14 |
| Est. Completion | 2021-03-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720941
The ClinicalTrials.gov registry entry for NCT00720941 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sunitinib is the first listed.
NCT00720941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720941 about?
NCT00720941 is a clinical study titled "Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma". This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.
What is the current status of trial NCT00720941?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,110 participants. The study started on 2008-08-14. Estimated completion is 2021-03-24.
What interventions are being tested in trial NCT00720941?
The interventions under investigation include: Sunitinib (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT00720941?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.